The first patient has been enrolled in a clinical trial evaluating IMNN-001, an immunotherapy, combined with Avastin for the treatment of advanced ovarian cancer.
The first patient has been enrolled in a phase 1/2 study to evaluate IMNN-001, an interleukin-12 immunotherapy, in combination with Avastin (bevacizumab) in patients with advanced ovarian cancer, according to a press release from IMNN-001’s manufacturer, Imunon.
The trial is now active at The University of Texas MD Anderson Cancer Center and is expected to enroll 50 patients with stage 3 or 4 advanced ovarian cancer. Patients who are undergoing neoadjuvant (pre-surgical) therapy will either chemotherapy alone or in combination with IMNN-001.
The main goal of the study is the detection of minimal residual disease (small amounts of cancer detectable after cancer) and initial data is expected within one year of enrollment completion. There is also a secondary goal of progression-free survival, which is the time patients live after treatment before their disease gets worse. Final data are expected three years after enrollment completion.
Researchers also plan to understand the clonal evolution and immunogenomic features of the minimal residual disease phase of ovarian cancer that is currently undetectable by imaging or tumor markers.
“The medical need for new innovative therapeutic approaches in ovarian cancer is major,” said Dr. Corrine Le Goff, president and chief executive officer of IMUNON, in the release. “The majority of patients with ovarian cancer are diagnosed with Stage 3/4 disease and face low cure rates of 15% or less. The amount of data this study will generate will be a huge contribution to the treatment of ovarian cancer and we believe the combination of IMNN-001 and (Avastin) has important potential. In our animal studies, the combination clearly showed strong synergies. We are hoping that with this study we can potentially transform the current treatment landscape and provide new hope to women suffering from this deadly cancer.”
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.